Shopping Cart
Remove All
Your shopping cart is currently empty
Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,620 | 4-6 weeks | 4-6 weeks | |
| 5 mg | $3,570 | 4-6 weeks | 4-6 weeks |
| Description | Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1]. |
| In vivo | Polatuzumab vedotin, at doses of 0.3, 1, 3, 6, and 12 mg/kg administered intravenously (i.v.) in a single administration, demonstrates anti-tumor activity in a mouse xenograft model of WSU-DLCL2 human diffuse large B-cell lymphoma [2]. |
| Cas No. | 1313206-42-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.